[go: up one dir, main page]

WO2001064229A1 - Medicament de traitement de l'obesite, sa preparation et son utilisation - Google Patents

Medicament de traitement de l'obesite, sa preparation et son utilisation Download PDF

Info

Publication number
WO2001064229A1
WO2001064229A1 PCT/CN2000/000037 CN0000037W WO0164229A1 WO 2001064229 A1 WO2001064229 A1 WO 2001064229A1 CN 0000037 W CN0000037 W CN 0000037W WO 0164229 A1 WO0164229 A1 WO 0164229A1
Authority
WO
WIPO (PCT)
Prior art keywords
servings
medicine
treating obesity
atractylodes
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2000/000037
Other languages
English (en)
Chinese (zh)
Inventor
Meibin Fujimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JUN HO CO Ltd
Original Assignee
JUN HO CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JUN HO CO Ltd filed Critical JUN HO CO Ltd
Priority to PCT/CN2000/000037 priority Critical patent/WO2001064229A1/fr
Priority to CN00819102.6A priority patent/CN1434717A/zh
Priority to AU2000229021A priority patent/AU2000229021A1/en
Priority to HK01101462A priority patent/HK1033066A2/xx
Publication of WO2001064229A1 publication Critical patent/WO2001064229A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/234—Cnidium (snowparsley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)

Definitions

  • the invention relates to a weight-loss medicine, in particular to a weight-loss medicine prepared by using a plant Chinese herbal medicine as a raw material.
  • the invention also relates to a method for preparing and using the slimming medicine. Background technique
  • Obesity refers to excessive calorie intake or excessive changes in the body's physiological and biochemical functions that lead to excessive fat storage in the body, obesity, and a weight that exceeds 10% of the standard weight. It is often accompanied by a series of metabolic disorders or neurological conditions, and is clinically prone to a variety of conditions such as arteriosclerosis, hypertension, diabetes, gout, cholangitis, cholelithiasis, impotence, and irregular menstruation. With the continuous improvement of people's living standards, the phenomenon of obesity is becoming more and more serious. In addition, obesity can also accelerate human aging, and the sudden death is significantly increased, so it should be given clinical attention.
  • the first is to eat low-fat, low-energy foods or alternative foods.
  • the second is edible digestion and absorption inhibitors.
  • the disadvantages of these two treatment methods are: easy rebound, no food satisfaction, heavy mental burden, easy to cause nutritional disorders, and obvious side effects such as abdominal pain and diarrhea.
  • CN94113251-X discloses a slimming drink made of thirteen Chinese herbal medicines and a preparation method thereof.
  • CN94116739- 9 discloses a manufacturing method and a product for slimming medicine containing more than 20 kinds of Chinese herbal medicine for internal administration. The products covered by these two patents are taken internally. Obviously, the disadvantages of the methods for treating obesity described above cannot be avoided.
  • CN94101824. 5 Discloses a natural bath liquid containing multiple flavors of Chinese herbal medicine and its preparation mainly for treating simple obesity.
  • CN93114999-1 Disclosed is a weight-loss fitness bath containing multiple flavors of Chinese herbal medicines for the treatment of obesity with alcohol bath.
  • CN93117263. 2 discloses a double-medicine core health care stomach medicine natural gourd containing 84 flavors of Chinese herbal medicine for treating various diseases.
  • the products disclosed in these patents are for external use and do not have the disadvantages of internal medicine, they are mainly health-care, and some of them are not specifically targeted at obesity.
  • the bath liquid is only used when the patient is taking a bath, the product in the form of a bath liquid has certain use limitations. Therefore, the efficacy of these products must be affected to some extent, and the effects are not always satisfactory.
  • the object of the present invention is to provide a medicine for treating obesity that has no side effects, is simple and easy to implement, is safe and reliable, has significant therapeutic effects, and can be consolidated and stabilized.
  • Another object of the present invention is to provide a method for preparing the medicine for treating obesity.
  • Another object of the present invention is to provide a method for using the medicine for treating obesity.
  • the invention provides a new medicine for treating obesity, which is made of Atractylodes macrocephala, Atractylodes macrocephala, Angelica sinensis, Salvia miltiorrhizae, Alisma orientalis, Snake seed, Mustard seed, Ephedra rhubarb, Rhubarb, Panax notoginseng as raw materials, and according to the prescription of each Chinese medicine Ingredients and properties are prepared by extraction.
  • the invention also provides a method for preparing the new medicine for treating obesity, in which rhubarb is extracted twice with 70% ethanol alone to make a thick paste; after the other drugs in the prescription are water-extracted and alcohol-precipitated, The ethanol was recovered under reduced pressure and concentrated to a thick paste.
  • the above two thick creams are combined, dissolved in a PEG mixed matrix solution, and optionally added an appropriate amount of a transdermal absorption enhancer, a surfactant, a preservative, water, etc. to prepare a salve.
  • the obtained ointment is poured into a plastic mold hole of an appropriate shape, and after appropriately cooling and molding, the plastic mold hole and the plastic mold are covered with a suitable carrier to prepare a patch.
  • the present invention also provides a method for using the medicine for treating obesity, which comprises: directly applying the ointment to the umbilicus (Shenque acupoint) or Guanyuan point (three inches below the umbilical cord), or opening the patch Packing, discarding the plastic mold, and sticking the side of Kelu medicine directly to the umbilicus (Shenxi point) or Guanyuan point (three inches below the umbilicus) according to the shape of the ointment, and then peel off the outer support film. Body temperature will dissolve the drug, apply it once a day, and use it 24 hours a day, stop it for one day a day, or stop for two days after using it.
  • a method for using the medicine for treating obesity comprises: directly applying the ointment to the umbilicus (Shenque acupoint) or Guanyuan point (three inches below the umbilical cord), or opening the patch Packing, discarding the plastic mold, and sticking the side of Kelu medicine directly to the umbilicus (Sh
  • the medicine for treating obesity is based on the theory of "internal disease and external treatment” in Chinese medicine, and adopts a natural therapy called “medicine umbilical method", which is based on the theory of traditional Chinese medicine meridian.
  • medicine umbilical method which is based on the theory of traditional Chinese medicine meridian.
  • the therapeutic yellow diarrhea drug is based on the above theory, and then advanced transdermal slow-release technology is used to make the drug reach the whole body through acupoint absorption. Regulates metabolic function, accelerates lipolysis, and has stable drug effect.
  • the medicine of the present invention is prepared by using traditional Chinese medicine plants as raw materials in combination at a certain ratio.
  • the specific raw materials are Astragalus, Atractylodes, Angelica, Salvia miltiorrhiza, Alisma, Snake Bed, Mustard, Ephedra, Rhubarb, Panax notoginseng and so on.
  • composition of the Chinese herbal medicine in the medicine of the present invention is as follows:
  • Atractylodes 3-12 parts Atractylodes 3-12 parts Huanghuang Angelica 3-15 parts Salvia 5-30 parts Alisma 6-30 parts Snake Bed 3-15 parts mustard 3-12 parts ephedra 2-12 parts rhubarb 3-30 parts Sanqi 2-10 servings
  • composition of the Chinese herbal medicine in the medicine of the present invention is as follows (weight ratio):
  • Atractylodes 5- 10 parts Atractylodes 5- 10 parts Angelica 5- 10 parts Danshen 5- 15 parts Alisma 10-20 parts Snake bed 5- 10 parts mustard 5-10 parts ephedra 5-10 parts rhubarb 5- 15 parts sanqi 2 -6 servings
  • composition of the Chinese herbal medicine in the medicine of the present invention is as follows (weight ratio):
  • the two herbs used in the Chinese herbal formula of the medicine of the present invention are commonly used Chinese herbs, and should first meet the standards of the Pharmacopoeia of the People's Republic of China to ensure the quality of the raw materials for drug use and the safety and effectiveness of the prepared drugs.
  • the topical patch in order to make the topical patch have a better effect, it is better to use authentic medicinal materials.
  • the medicine of the invention is based on the theory of "internal disease and external treatment” in traditional Chinese medicine and the theory of traditional Chinese medicine meridian
  • the traditional black medicinal ointment preparation technology in traditional Chinese medicine is combined with new materials and new processes in modern pharmacy.
  • the drug can play the role of participating in the meridian, removing stasis and removing blood stasis, and stimulate the meridian in the entire prescription of the drug, dredge the meridian, and promote the operation of qi and blood to adjust the function of the viscera.
  • coordinate the body's yin and yang balance so as to achieve the purpose of internal disease and external treatment.
  • the mechanism of the traditional Chinese medicine plaster is consistent with the transdermal drug delivery system in modern medicine.
  • TDS transdermal therapeutic system
  • the medicament for treating obesity of the present invention may be any of the pharmacologically stated dosage forms.
  • the medicament for treating obesity of the present invention may include excipients such as a matrix, a transdermal absorption enhancer, a surfactant, a preservative, water, and other additives commonly used in the art.
  • the medicament for treating obesity of the present invention is preferably used as an external ointment.
  • the content of traditional Chinese medicine generally accounts for 20-40%
  • the content of excipients generally accounts for 60-80%.
  • the bases used in the medicament of the present invention may be those bases commonly used in the field of formulations for external films, ointments, emulsions, patches (including plasters), and the like.
  • Black plaster is a lead plaster made from medicinal materials, edible vegetable oil and red dan.
  • the solvent used in the extraction is vegetable oil, but vegetable oil can only dissolve some non-polar substances, and the effective ingredients such as alkaloids contained in general medicinal materials are often combined with organic acids to form salts in cells, so they are not soluble in oil.
  • ointments are generally used in greasy bases, including greases, lipids and hydrocarbons. Its common features are lubricating, non-irritating, stronger protection and softening effect than other matrices, and can cooperate with more drugs. However, it is greasy and hydrophobic, water-soluble components are not easy to dissolve, and it is not easy to wash away with water. The release and penetration of drugs are smaller than those of other matrices.
  • the emulsion-type matrix is similar to the emulsion, and is a semi-solid state matrix formed by the action of an aqueous phase and an oil phase with the aid of an emulsifier.
  • Water-in-oil and water-in-oil are water-in-oil.
  • the water-in-oil emulsion base looks like an ointment, is easier to apply than a greasy base, has less greasiness, and has a cooling effect when moisture evaporates from the skin surface.
  • the oil-in-water emulsion base looks like vanishing cream, can be mixed with water, is non-greasy and easy to remove.
  • the water-soluble base is non-lipid, and is also called a hydrogel ointment base. It consists of natural or synthetic polymer-soluble substances.
  • the water-soluble matrix can be mixed with aqueous body fluids, absorb tissue fluids, and generally release drugs quickly, without oiliness, and easy to spread and wash away. It is non-irritating to the skin and mucous membranes, and can be used for erosive wounds and luminal mucosa.
  • the disadvantage is that it has poor lubricating effect and is easy to lose water and dry. Therefore, it is necessary to add humectants and preservatives.
  • the matrix in the medicament of the present invention is preferably a polyethylene glycol substance having a different molecular weight, and is formulated according to different formulation ratios.
  • polyethylene glycols are non-toxic and irritating to the human body, have stable chemical properties, are heat resistant, and are not prone to rancidity and mold. Because this product has a wide range of solubility, compatibility, film-forming, plasticizing, dispersibility, etc., this product with a smaller molecular weight is used as a solvent, co-solvent and oil / water emulsion stabilizer, used in water mixing Preparation of suspensions, emulsions, injections, etc. Because they are very stable, non-irritating to the skin and lubricating, they are used as water-soluble ointment bases and suppository bases, for manufacturing creams, suppositories, and the like. For drugs that are not easily dissolved in water, this product can be used for the purpose of solid dispersion, improve the solubility or solubility of drugs and increase pharmacological activity.
  • the preparation is in a near-solid state below, plus its own hypertonic state, it is not easy to grow mold, not easy to spoil, and has good stability.
  • the chemical components contained in it are also relatively stable and difficult to decompose. Deterioration. This is also an excellent advantage of the drugs prepared by the present invention.
  • the substrates that can be specifically mentioned are PEG400, PEG1000, and PEG4000. They are the two varieties contained in the 1995 edition of the Pharmacopoeia of the People's Republic of China, and they are formulated in a certain proportion. Melted at body surface temperature of about 35.
  • the content of PEG400 accounts for 2-8%
  • the content of PEG1000 accounts for 30-50%
  • the content of PEG4000 accounts for 15-45%.
  • the content of the matrix generally accounts for 44.7-78.9%, preferably 60-70%.
  • a transdermal absorption-promoting agent may be optionally used. It is generally believed that when the transdermal absorption agent acts on the skin, by changing the skin permeability, the diffusivity of the active ingredient or the solubility of the drug is increased, resulting in an increase in the permeability of the drug, thereby achieving the ultimate goal of promoting transdermal absorption. .
  • the invention preferably uses a small amount of a transdermal absorption enhancer to enhance the transdermal absorption of the drug and improve its efficacy. Based on the total weight of the finished finished ointment, the transdermal absorption enhancer generally accounts for 0.5 to 10%, preferably 1%.
  • the transdermal absorption agent used in the present invention may be any transdermal absorption agent commonly used in the art for this purpose.
  • the transdermal absorption-promoting agent used in the present invention is preferably Azone, and its chemical name is 1-dodecyl-hexahydro-2H-azapyridin-2-one. It is also included in the second part of the 1995 Pharmacopoeia of the People's Republic of China, so its quality should meet the requirements.
  • a transdermal absorption-promoting agent, azatone, which is added to the medicament of the present invention, is a new type of highly effective and low toxicity penetration enhancer. It is a colorless, almost odorless liquid, insoluble in water, lubricating, non-irritating to human skin, mucous membranes and cavity membranes, and low toxicity.
  • Azone is a non-polar transdermal absorption agent. The mechanism of action is believed to soften the keratin, coagulate tissue proteins, enhance permeability, allow the drug to penetrate the skin barrier, increase local or systemic blood drug concentration, and increase the bioavailability of the preparation, thereby obtaining a more ideal therapeutic effect.
  • a surfactant may be optionally used in the medicament for treating obesity of the present invention.
  • Adding a surfactant to the matrix can increase the solubility of insoluble pharmaceutical ingredients in the water and increase the water absorption of the matrix used, so that the pharmaceutical ingredients have better solubility in the matrix, and also promote the penetration of the drug.
  • ⁇ Sex agent.
  • the non-ionic active agent Tween-80 is used as the surfactant of the present invention. This product has obvious adaptability to different pH, and also coexists with high concentration of electrolyte. More stable. Very little irritation and toxicity to the skin.
  • the content of the surfactant generally accounts for
  • Preservatives are optionally used in the medicament for treating obesity of the present invention.
  • the present invention can use any preservative commonly used in the art.
  • the matrix used in the medicine of the present invention accounts for a large proportion, its solution is in a hypertonic state, and microorganisms are not easy to grow.
  • the storage temperature of this product is below 25, it is preferable to use a preservative in the medicine of the present invention.
  • the preferred preservative is chlorhexidine, because according to the literature, polyethylene glycols may reduce the bacteriostatic effect of benzoate preservatives, while chlorhexidine is not affected so much, so the amount has not increased.
  • the preservative based on the total weight of the finished ointment, the preservative generally accounts for 0.1 0.3%, preferably 0.1%.
  • the medicine of the present invention may contain an appropriate amount of water. Based on the total weight of the finished ointment of the present invention, the water content generally accounts for 0-30%.
  • the medicament of the present invention may optionally contain other additives commonly used in the art, which is selected according to the specific purpose desired.
  • the invention also provides a method for preparing the novel medicine for treating obesity.
  • rhubarb was extracted twice with 70% ethanol alone to make a thick paste; after the other drugs in the prescription were water-extracted and alcohol-precipitated, ethanol was recovered under reduced pressure and concentrated to a thick paste.
  • the two thick pastes are combined, dissolved in a PEG mixed matrix solution, and optionally added an appropriate amount of a transdermal absorption enhancer, a surfactant, a preservative, water, and other commonly used additives to prepare a salve.
  • the obtained ointment is poured into a plastic mold hole of an appropriate shape, and after being appropriately cooled and formed, the plastic mold hole and the plastic mold are covered with a suitable carrier to prepare a patch,
  • 1 gram of the thick paste is equivalent to 1 gram of crude medicine.
  • the specific situation will be slightly different depending on the location and season of the crude medicine.
  • a transdermal absorption enhancer a surfactant, a preservative and water are preferably added.
  • the obtained ointment is poured into a conical plastic mold hole to prepare a conical patch.
  • the present invention also provides a method for using the medicine for treating obesity, which comprises: directly applying the ointment to the umbilicus (Shenque acupoint) or Guanyuan point (three inches below the umbilical cord), or opening the patch Packing, discarding the plastic mold, sticking the side of Kelu medicine directly to the umbilicus (Shenxi point) or Guanyuan point (three inches below the umbilicus) according to the shape of the ointment, and then peel off the outer support film, about 35 Body temperature will dissolve the drug, apply it once a day, use it 24 hours a day, stop it one day a day or Stop for one day after taking two patches.
  • the cone tip of the above-mentioned tape-shaped patch is aligned with the umbilical cord and depressed into the acupoint or directly stuck to the Guanyuan point.
  • the medicament for treating obesity of the present invention When used externally as an ointment, it can be directly applied.
  • the plaster is applied and supported on a suitable carrier material. All carrier materials commonly used in the art for this purpose are suitable for use in the present invention.
  • the characteristics of the carrier material of the present invention are:
  • the carrier is composed of a sponge pad and a special waterproof and breathable film
  • the special waterproof and breathable film is made of, for example, a synthetic resin and an acrylic adhesive.
  • the medicine for treating obesity of the present invention is used as a topical patch, it is applied to the navel (Shenque Acupoint) or Guanyuan Point (three inches below the umbilical cord), and it is used once every two days, or it is stopped for two days and one day, and each patch uses 24 For those who lose more than 1kg per day, please stop posting for two days.
  • the medicine of the present invention After the medicine of the present invention is applied to the selected part for a period of time as required, the medicine will naturally and slowly melt, and the pharmaceutical ingredients enter the body and function. You can feel the peristalsis in the large intestine, increase the exhaust, no hunger, and love vegetarian food. Individual skin temperature is too low, you can apply a warm patch to the medication site (note that the temperature should be softened to a degree not to soften the drug and improve the efficacy. When using the drug of the present invention, it should be noted that: (1) the navel has The ulcer is disabled, (2) Allergic reactions occur and should be discontinued.
  • the medicine for treating obesity of the present invention is used as a topical medicine, it is a new type of topical health-care weight-loss medicine, which is refined from pure Chinese medicine. It does not contain any harmful ingredients, and is safe and convenient to use. It should be affixed to the navel (Shenxi Acupoint) daily. It can effectively regulate the body's fat metabolism through acupoint administration. The whole body weight loss effect is obvious, especially for waist, abdomen and buttocks. No dieting, no diarrhea, no rebound, long-lasting and stable effect.
  • the medicament of the present invention is applicable to various types of obesity.
  • the Chinese herbal formula in the medicine for treating obesity of the present invention is preferably used in the external plaster of the present invention, but it does not exclude that they are directly or made into any appropriate pharmacy Use on an acceptable dosage form.
  • Example Example 1 illustrates the invention. However, the following examples are merely illustrative, and do not limit the present invention in any respect.
  • Example Example 1 illustrates the invention. However, the following examples are merely illustrative, and do not limit the present invention in any respect.
  • Example Example 1 illustrates the invention. However, the following examples are merely illustrative, and do not limit the present invention in any respect.
  • Example Example 1 illustrates the invention. However, the following examples are merely illustrative, and do not limit the present invention in any respect.
  • Atractylodes 200g Atractylodes 200g, Rhubarb 200g, Ephedra 200g, Angelica 200g, Panax notoginseng 80g, Salvia miltiorrhiza 200g, Mustard 200g, Alisma 400g, Snake bed 200g
  • the two filtrates were combined, the ethanol was recovered under reduced pressure, and concentrated to a non-alcoholic taste, and then used.
  • the other traditional Chinese medicines in the formula were extracted twice with hot reflux using water as a solvent. Add 10 times the amount of water for the first time, soak for 1 hour, heat and extract for 1.5 hours, and filter; add 8 times the amount of water for the second time, heat and extract for 1 hour, and filter.
  • the two filtrates were combined and concentrated under reduced pressure to about 1.2 g of medicinal material per 1 ml of medicinal solution. Add 95% ethanol to an alcohol content of 60% for alcohol precipitation, and let stand for 24 hours.
  • the medicines prepared above were clinically treated in 56 patients according to the above usage and dosage.
  • the basic situation of the patients was: Among the 56 patients, 24 were male patients, aged 18 to 65 years, with an average age of 45.8 years. Weight was 20% above normal weight; 32 female patients, aged 21 to 69 years, with an average age of 48.3 years, and average weight over 25%. After 30 days, the results of clinical observation were that 47 people were significantly effective, and the effective rate was 83.9%; 7 were effective, and the effective rate was 12.5%; and 2 were ineffective, and the invalid rate was 3.6%. After 3 months of treatment, the average monthly weight loss was more than 5% of body weight.
  • Atractylodes 120g Atractylodes 120g, Rhubarb 120g
  • Atractylodes 480g Atractylodes 480g Rhubarb 1200g

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un médicament de traitement de l'obésité se composant d'extraits d'Atractylodes macrocephala, Atractylodes lancea ou a. chinensis, Angelica sinensis, Saliva miltiorrhiza, alisma orientalis, Cnidium monnieri, Sinapis alba ou brassica juncea, Ephedra sinica, E. equisetina ou E. intermedia, Rheum palmatum. R. tanguticum ou R. officinale, Panax notoginseng. Le médicament est spécialement indiqué à un usage externe. L'invention concerne également son procédé de production et son utilisation.
PCT/CN2000/000037 2000-02-29 2000-02-29 Medicament de traitement de l'obesite, sa preparation et son utilisation Ceased WO2001064229A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/CN2000/000037 WO2001064229A1 (fr) 2000-02-29 2000-02-29 Medicament de traitement de l'obesite, sa preparation et son utilisation
CN00819102.6A CN1434717A (zh) 2000-02-29 2000-02-29 一种减肥药及其制备和应用
AU2000229021A AU2000229021A1 (en) 2000-02-29 2000-02-29 A medicine for treating obesity and the method of producing thereof
HK01101462A HK1033066A2 (en) 2000-02-29 2001-02-28 A diet medicament with its manufacture and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2000/000037 WO2001064229A1 (fr) 2000-02-29 2000-02-29 Medicament de traitement de l'obesite, sa preparation et son utilisation

Publications (1)

Publication Number Publication Date
WO2001064229A1 true WO2001064229A1 (fr) 2001-09-07

Family

ID=4574634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000037 Ceased WO2001064229A1 (fr) 2000-02-29 2000-02-29 Medicament de traitement de l'obesite, sa preparation et son utilisation

Country Status (4)

Country Link
CN (1) CN1434717A (fr)
AU (1) AU2000229021A1 (fr)
HK (1) HK1033066A2 (fr)
WO (1) WO2001064229A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058284A1 (fr) * 2002-12-27 2004-07-15 Korea Institute Of Oriental Medicine Ingredients anti-obesite obtenus a partir de plantes medicinales et leur composition
US7300675B2 (en) * 2003-07-29 2007-11-27 Kao Corporation Lipolysis stimulator
EP1706108A4 (fr) * 2003-12-30 2009-08-12 Md Bioalpha Co Ltd Traitement de l'obesite et du syndrome metabolique avec des derives de tanshinone augmentant l'activite metabolique
WO2009133430A1 (fr) * 2008-04-30 2009-11-05 Wockhardt Research Centre Compositions topiques de rhéine ou de diacéréine
US8717637B2 (en) 2011-11-30 2014-05-06 Kodak Alaris Inc. Method for scanning documents
US8860989B2 (en) 2011-12-15 2014-10-14 Kodak Alaris Inc. Scanner with exception preview
US9278155B2 (en) 2003-06-05 2016-03-08 3M Innovative Properties Company Adhesive compositions, articles incorporating same and methods of manufacture
CN105943773A (zh) * 2016-06-23 2016-09-21 河南中医学院 一种用于单纯性肥胖症的中药穴贴

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033895A (zh) * 1987-11-05 1989-07-12 长沙电缆附件厂 电缆附件用聚氨酯浇注树脂的制备方法
CN1107691A (zh) * 1994-03-02 1995-09-06 赵新胜 消肥益寿天然保健浴液及其配制
CN1108542A (zh) * 1993-09-08 1995-09-20 王印豪 双药芯保健兜肚浑天药葫芦
CN1145794A (zh) * 1995-09-20 1997-03-26 金建文 贴脐减肥膏

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033895A (zh) * 1987-11-05 1989-07-12 长沙电缆附件厂 电缆附件用聚氨酯浇注树脂的制备方法
CN1108542A (zh) * 1993-09-08 1995-09-20 王印豪 双药芯保健兜肚浑天药葫芦
CN1107691A (zh) * 1994-03-02 1995-09-06 赵新胜 消肥益寿天然保健浴液及其配制
CN1145794A (zh) * 1995-09-20 1997-03-26 金建文 贴脐减肥膏

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058284A1 (fr) * 2002-12-27 2004-07-15 Korea Institute Of Oriental Medicine Ingredients anti-obesite obtenus a partir de plantes medicinales et leur composition
US9278155B2 (en) 2003-06-05 2016-03-08 3M Innovative Properties Company Adhesive compositions, articles incorporating same and methods of manufacture
US7300675B2 (en) * 2003-07-29 2007-11-27 Kao Corporation Lipolysis stimulator
EP1706108A4 (fr) * 2003-12-30 2009-08-12 Md Bioalpha Co Ltd Traitement de l'obesite et du syndrome metabolique avec des derives de tanshinone augmentant l'activite metabolique
WO2009133430A1 (fr) * 2008-04-30 2009-11-05 Wockhardt Research Centre Compositions topiques de rhéine ou de diacéréine
US8717637B2 (en) 2011-11-30 2014-05-06 Kodak Alaris Inc. Method for scanning documents
US8860989B2 (en) 2011-12-15 2014-10-14 Kodak Alaris Inc. Scanner with exception preview
CN105943773A (zh) * 2016-06-23 2016-09-21 河南中医学院 一种用于单纯性肥胖症的中药穴贴

Also Published As

Publication number Publication date
CN1434717A (zh) 2003-08-06
HK1033066A2 (en) 2001-07-27
AU2000229021A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
CN103169928B (zh) 治疗痛经的外用中药组合物及其制备方法和应用
CN105833279A (zh) 皮肤多种损伤创面治疗的外用药物组合物及其制备方法
CN103751633A (zh) 一种治疗下肢静脉曲张的中药组合物及其制备方法
WO2001064229A1 (fr) Medicament de traitement de l'obesite, sa preparation et son utilisation
JPH07300423A (ja) 早発射精予防用または治療用医薬組成物
KR100358819B1 (ko) 생약 패취제
CN101934015A (zh) 一种治疗甲状腺的中药组合物及其散瘿巴布剂的制备方法
CN108403939A (zh) 治疗痔疮及便秘的中药复方制剂及所用中药组合物
CN101926857B (zh) 治疗白癜风的中药擦剂
CN104547056B (zh) 一种治疗小儿腹泻的外用脐部贴剂及其制备方法
CN103655735B (zh) 一种治疗脚气、皮肤瘙痒症泡洗剂
CN101926911B (zh) 一种止痛的中药组合物及其制备方法
CN106860718A (zh) 一种足浴粉及其制备方法
CN105055685A (zh) 一种治疗冻疮的药膏及其制备方法
CN104857392A (zh) 一种治疗霉菌性阴道炎的阴道栓及其制备使用方法
CN112870316B (zh) 一种用于治疗糖尿病周围神经病变的中药组合物及中药敷贴
CN110384785A (zh) 一种用于治疗病毒性感冒的外用中药药液及其制备方法
CN110090285A (zh) 一种治疗坐骨神经痛的膏药及其制备方法
CN110269926A (zh) 温中舒暖组合物及其制备方法和应用
CN102631497B (zh) 一种保健组合物
JP6943941B2 (ja) レモンバーム抽出物を有効成分として含む注射剤及び化粧料組成物
KR20030043326A (ko) 성기능 장애 치료용 생약 조성물
CN106177590A (zh) 一种用于治疗小儿抽动秽语综合征的中药胶囊
KR20080105857A (ko) 치질환 및 기타 항문 직장 질환 치료 활성을 가지는조성물과 이의 제조 방법 및 이를 이용한 치질환 치료제
CN121015814A (zh) 一种行经祛瘀的中药组合物、外用制剂及用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 008191026

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase